Financials data is unavailable for this security.
View more
Year on year Novartis AG grew revenues 7.57% from 43.38bn to 46.66bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 113.52% net income growth from 6.96bn to 14.85bn.
| Gross margin | 74.61% |
|---|---|
| Net profit margin | 19.09% |
| Operating margin | 21.86% |
| Return on assets | 8.82% |
|---|---|
| Return on equity | 19.86% |
| Return on investment | 12.43% |
More ▼
Cash flow in USDView more
In 2023, Novartis AG increased its cash reserves by 78.17%, or 5.88bn. The company earned 14.46bn from its operations for a Cash Flow Margin of 30.99%. In addition the company generated 5.60bn cash from investing, though they paid out 14.28bn more in financing than they received.
| Cash flow per share | 7.61 |
|---|---|
| Price/Cash flow per share | 12.55 |
| Book value per share | 18.37 |
|---|---|
| Tangible book value per share | -4.47 |
More ▼
Balance sheet in USDView more
| Current ratio | 0.903 |
|---|---|
| Quick ratio | 0.7069 |
| Total debt/total equity | 0.6855 |
|---|---|
| Total debt/total capital | 0.4062 |
More ▼
Growth rates in USD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 13.28% and 48.75%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.
| Div yield(5 year avg) | 3.68% |
|---|---|
| Div growth rate (5 year) | 6.19% |
| Payout ratio (TTM) | 77.34% |
| EPS growth(5 years) | -5.59 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 58.09 |
More ▼
